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Figure S1: Project Viva cohort sample size and participation. 665 participants had data available 
for at least one exposure and one outcome studied. 
 
Figure S2: Covariate-adjusted associations of mid-childhood PFAS plasma concentrations and 
HOMA-IR measured at the same time (median: 7.7 years of age) modeled using penalized 
splines. Maximum and minimum values for each PFAS quartile are overlaid on the spline 
graphs.
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Table S1.  Characteristics of Project Viva participants in the full cohort and in the subset not included versus included in analyses. 
  
Full cohort  
(n=2,128) 
Subset not included in 
analyses (n=1,463) 
Subset included in 
analyses (n=665) 
 N 
Median (IQR) 
or % N 
Median (IQR) 
or % N 
Median (IQR) 
or % 
Maternal characteristics       
Age at enrollment (years) 2,128 32.2 (6.4) 1,463 32.1 (6) 665 32.5 (7.1) 
Prepregnancy BMI (kg/m2) 2,112 23.5 (6.4) 1,451 23.3 (6.4) 661 23.7 (5.9) 
Nulliparous (%) 2,128 48 1,463 50 665 42 
College graduate (%) 2,104 65 1,443 65 661 64 
Smoking habits (%) 2,107  1,443  664  
Never  68  68  69 
Former  19  19  19 
During pregnancy  13  13  11 
Maternal PFAS plasma concentration (ng/mL) 1,645  1,109  536  
PFOA  5.8 (3.8)  6 (3.7)  5.4 (3.8) 
PFOS  25.7 (16.0)  26.3 (16.1)  24.4 (16.1) 
PFNA  0.7 (0.4)  0.7 (0.5)  0.6 (0.4) 
PFHxS  2.4 (2.2)  2.5 (2.1)  2.4 (2.2) 
Time of maternal PFAS measurement (weeks 
gestation) 1,168 9.7 (2.3) 
1,122 
 9.7 (2.3) 546 9.6 (2.1) 
       Partner/ Household/Neighborhood 
characteristics at enrollment       
Median household income in census tract ($) 2,108 53,934 (26,821) 1,451 54,688 (26,483) 657 51,798 (28,921) 
Percent below poverty in census tract (%) 2,108 7.1 (10.6) 1,451 6.8 (9.9) 657 7.4 (11.8) 
       
Child characteristics       
Female (%) 2,128 48 1,463 49 665 47 
Race/ethnicity (%)c 2,109  1,446  663  
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Abbreviations:	BMI:	body	mass	index;	interquartile	range;	PFAS:	perfluoroalkyl	substances;	PFOA:	perfluorooctanoate;	PFOS:	
perfluorooctane	sulfonate;	PFNA:	perfluorononanoate;	PFHxS:	perfluorohexane	sulfonate;	PFDeA:	perfluorodecanoate	
 
  
White  64  66  59 
Black  17  15  22 
Hispanic  6  6  5 
Asian  5  5  2 
Other  9  8  11 
Age at mid-childhood visit (years) 1,116 7.7 (1.1) 457 7.7 (1.1) 665 7.7 (1.0) 
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Table S2. Distributions of child plasma concentrations of linear and branched isomers of PFOA 
and PFOS with greater than 65% of detectable values 
Exposure n-PFOA n-PFOS Sm-PFOS 
N 643 643 643 
Geometric mean 
(25th, 75th %ile) 4.0 (3.0, 5.7) 4.5 (3.0, 7.1) 1.7 (1.1, 2.8) 
Minimum 0.1 0.1 0.1 
Maximum 13.8 34.2 16.8 
% below LOD 0.5 0.5 0.5 
Abbreviations: PFOA: perfluorooctanoate; PFOS: perfluorooctane sulfonate; n-PFOA: linear 
perfluorooctanoate; n-PFOS: linear perfluorooctane sulfonate; Sm-PFOS: sum of 
perfluoromethylheptane sulfonates; LOD: limit of detection 
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Table S3. Characteristics of Project Viva participants by PFOA plasma concentration in mid-childhood 
(n=643 in analytic dataset with measurement of PFOA in mid-childhood)a 
Quartilesb of child PFOA 
Q1 (lowest) 
  
Q2 
 
Q3 
 
Q4 (highest) 
  n=160 n=160 n=164 n=159 
Median (IQR) or % 
Maternal characteristics 
Age at enrollment (years) 30.8 (10.6) 32.9 (7.2) 32.7 (5.9) 33.1 (6.1) 
College graduate (%)c 42 65 71 79 
Household/Neighborhood characteristics 
Median household income in census tract ($)d 50,305 
(26,716) 
60,414 
(29,418) 
61,231 
(23,855) 
68,533 
(29,799) 
Percent below poverty in census tract (%)d 7.4 (13.0) 4.7 (7.4) 4.2 (3.9) 3.7 (3.6) 
Child characteristics 
Female (%) 47 49 44 48 
Race/ethnicity (%)e 
White 28 60 66 82 
Black 45 20 15 7 
Hispanic 9 7 5 1 
Asian 4 2 2 3 
Other 14 11 12 8 
Age at mid-childhood visit (years) 8.2 (1.7) 7.7 (1.1) 7.7 (0.7) 7.6 (0.6) 
Leptin (ng/mL) 4.3 (6.7) 3.3 (3.9) 2.6 (3.6) 3.1 (3.0) 
Adiponectin (µg/mL) 12.1 (11.1) 14.6 (8.6) 15.0 (8.7) 14.3 (8.5) 
HOMA-IR 1.8 (1.9) 1.6 (1.1) 1.3 (1.4) 1.3 (1.2) 
Abbreviations: HOMA-IR: homeostatic model assessment of insulin resistance; IQR: 
interquartile range; PFOA: perfluorooctanoate; Q1: quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: 
quartile 4 
aMissing data as follows: 4 participants missing maternal education, 6 census tract variables, 2 
race/ethnicity, 50 leptin, 50 adiponectin, 92 HOMA-IR 
bPFOA maximum and minimum values: < LOD (0.1)-3.0 ng/mL for Q1, 3.1-4.3 ng/mL for Q2, 
4.4-6.0 ng/mL for Q3, and 6.1-14.3 ng/mL for Q4 
cAt time of enrollment (median 9.6 weeks gestation) 
dAt time of mid-childhood follow-up visit (median 7.7 years) 
eMaternal race/ethnicity was substituted in 10% of children whose race/ethnicity was missing. 
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Table S4. Covariate-adjusteda associations of mid-childhood PFAS plasma concentration 
(median: 7.7 years of age) with ln-transformed HOMA-IR measured at the same time in female 
versus male children.   
 Females n=257 
Males 
n=284 
 Estimate (95% CI) for percent change in HOMA-IR 
PFOA   
IQR (2.9 ng/mL) -15.6 (-25.4, -4.6) -6.1 (-16.2, 5.2) 
Q1 [<LOD (0.1)-3.0 ng/mL] Reference Reference 
Q2 (3.1-4.3 ng/mL) -28.6 (-45.6, -6.2) -5.0 (-26.8, 23.2) 
Q3 (4.4-6.0 ng/mL) -32.8 (-49.7, -10.3) -25.3 (-42.4, -3.0) 
Q4 (6.1-14.3 ng/mL) -39.5 (-54.7, -19.3) -13.1 (-34.1, 14.6) 
PFOS   
IQR (5.5 ng/mL) -16.7 (-25.7, -6.7) -6.2 (-14.7, 3.1) 
Q1 [<LOD (0.1)-4.2 ng/mL] Reference Reference 
Q2 (4.2-6.2 ng/mL) 5.9 (-18.2, 37.0) 0.4 (-21.7, 28.8) 
Q3 (6.2-9.7 ng/mL) -11.4 (-32.5, 16.3) -17.4 (-36.1, 6.7) 
Q4 (9.8-51.4 ng/mL) -30.7 (-47.5, -8.4) -21.9 (-40.1, 1.8) 
PFNA   
IQR (1.2 ng/mL) -2.7 (-7.3, 2.1) 1.0 (-3.0, 5.2) 
Q1 [<LOD (0.1)-1.0 ng/mL] Reference Reference 
Q2 (1.1-1.5 ng/mL) -34.0 (-49.0, -14.6) -18.3 (-35.6, 3.7) 
Q3 (1.6-2.3 ng/mL) -25.5 (-43.9, -1.0) -30.4 (-45.8, -10.6) 
Q4 (2.4-25.7 ng/mL) -32.8 (-48.6, -12.1) -15.8 (-34.4, 8.2) 
PFHxS   
IQR (2.2 ng/mL) -1.8 ( -5.1, 1.6) -1.9 (-4.6, 0.9) 
Q1 [<LOD (0.1)-1.1 ng/mL] Reference Reference 
Q2 (1.2-1.9 ng/mL) -11.7 ( -32, 14.6) -3.1 (-25, 25.2) 
Q3 (2.0-3.4 ng/mL) -22.2 ( -40.6, 1.9) 7.6 (-17.7, 40.5) 
Q4 (3.5-56.8 ng/mL) -24.6 ( -43.6, 0.8) -13.5 (-33.3, 12.1) 
PFDeA   
IQR (0.3 ng/mL) -22.2 (-32.0, -11.1) -8.3 (-19.1, 4.0) 
Q1 [<LOD (0.1)-0.2 ng/mL] Reference Reference 
Q2 (≥0.3-<0.4 ng/mL) -10.6 (-31.4, 16.6) -10.0 (-29.0, 14.1) 
Q3 (≥0.4-<0.5 ng/mL) -32.5 (-48.2, -11.9) -32.6 (-47.9, -12.7) 
Q4 (0.5-1.9 ng/mL) -36.0 (-50.4, -17.4) -7.9 (-27.5, 17.0) 
Estimates are presented as percent change (95% confidence intervals) in outcome for (1) 
concentration quartiles 2-4 versus quartile 1 and (2) for each interquartile range increment in 
concentrations. Estimates with 95% confidence intervals that do not cross the null are bolded. 
Abbreviations: HOMA-IR: homeostatic model assessment of insulin resistance; IQR: 
interquartile range; LOD: limit of detection; PFAS: perfluoroalkyl substances; PFOA: 
perfluorooctanoate; PFOS: perfluorooctane sulfonate; PFNA: perfluorononanoate; PFHxS: 
perfluorohexane sulfonate; PFDeA: perfluorodecanoate; Q1: quartile 1; Q2: quartile 2; Q3: 
quartile 3; Q4: quartile 4 
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aModel adjusted for characteristics of child (age, race/ethnicity), mother (age, education), and 
neighborhood census tract at mid-childhood (median household income, percent below poverty) 
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Figure S1. Project Viva cohort sample size and participation. 665 participants had data available for at least 
one exposure and one outcome studied.
2,128 live births
1,116 with mid-childhood 
visit
667 with measurement of 
leptin, adiponectin, or 
HOMA-IR in mid-childhood
536 with measurement of 
PFAS in prenatal plasma
• 491 with leptin/adiponectin
• 451 with HOMA-IR
665 with measurement of 
PFAS in prenatal or child 
plasma 
643 with measurement of PFAS 
in mid-childhood plasma
• 593 with leptin/adiponectin
• 551 with HOMA-IR
In covariate-adjusted analyses 
of prenatal PFAS:  
• 484 with leptin/adiponectin 
• 441 with HOMA-IR             
In covariate-adjusted analyses of 
mid-childhood PFAS:  
• 584 with leptin/adiponectin 
• 541 with HOMA-IR             
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Figure S2. Covariate-adjusteda associations of mid-childhood PFAS plasma concentrations and 
HOMA-IR measured at the same time (median: 7.7 years of age) modeled using penalized 
splines. Maximum and minimum values for each PFAS quartile are overlaid on the spline 
graphs. 
		 	
	
		 	
Abbreviations: HOMA-IR: homeostatic model assessment of insulin resistance; PFAS: 
perfluoroalkyl substances; PFOA: perfluorooctanoate; PFOS: perfluorooctane sulfonate; PFNA: 
perfluorononanoate; PFHxS: perfluorohexane sulfonate; PFDeA: perfluorodecanoate; Q1: 
quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: quartile 4 
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aModel adjusted for characteristics of child (age, sex, race/ethnicity), mother (age, education), 
and neighborhood census tract at mid-childhood (median household income, percent below 
poverty)  
